Older patients and residents with tardive dyskinesia require special considerations. Learn about phenomenology, prevalence, and management guidelines for tardive dyskinesia in this population. Faculty will share clinical data for an FDA-approved treatment option for adults with tardive dyskinesia and highlight data from a post hoc analysis of safety and efficacy for adults aged 65 years and older. Participants will also be able to examine the case of a patient with tardive dyskinesia by observing videos of the patient before and after treatment. This non-CME educational program is sponsored by Neurocrine Biosciences, Inc.